1
|
González-Martín A, Harter P, Leary A, Lorusso D, Miller RE, Pothuri B, Ray-Coquard I, Tan DSP, Bellet E, Oaknin A, Ledermann JA. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2023; 34:833-848. [PMID: 37597580 DOI: 10.1016/j.annonc.2023.07.011] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2023] [Revised: 07/26/2023] [Accepted: 07/28/2023] [Indexed: 08/21/2023] Open
Affiliation(s)
- A González-Martín
- Department of Medical Oncology and Program in Solid Tumors Cima-Universidad de Navarra, Cancer Center Clínica Universidad de Navarra, Madrid and Pamplona, Spain
| | - P Harter
- Department of Gynecology and Gynecologic Oncology, Ev. Kliniken Essen-Mitte, Essen, Germany
| | - A Leary
- Department of Medical Oncology, Gustave Roussy Cancer Center, INSERM U981, Université Paris-Saclay, Paris, France
| | - D Lorusso
- Division of Gynecologic Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Rome; Department of Woman, Child and Public Health, Catholic University of the Sacred Heart, Rome, Italy
| | - R E Miller
- Department of Medical Oncology, University College Hospital, London; Department of Medical Oncology, St Bartholomew's Hospital, London, UK
| | - B Pothuri
- Department of Obstetrics and Gynecology, Perlmutter Cancer Center, NYU Langone Health, New York University School of Medicine, New York, USA
| | - I Ray-Coquard
- Department of Medical Oncology, Centre Leon Bernard and Université Claude Bernard Lyon I, Lyon, France
| | - D S P Tan
- Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; National University of Singapore (NUS) Centre for Cancer Research, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore; Cancer Science Institute, National University of Singapore, Singapore, Singapore; Department of Haematology-Oncology, National University Cancer Institute, National University Hospital, Singapore, Singapore
| | - E Bellet
- ACTO-Alleanza contro il Tumore Ovarico, Milan, Italy
| | - A Oaknin
- Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
| | - J A Ledermann
- Department of Oncology, UCL Cancer Institute, University College London, London, UK
| |
Collapse
|
2
|
Pothuri B, Blank SV, Myers TK, Hines JF, Randall LM, O'Cearbhaill RE, Slomovitz BM, Eskander RN, Alvarez Secord A, Coleman RL, Walker JL, Monk BJ, Moore KN, O'Malley DM, Copeland LJ, Herzog TJ. Inclusion, diversity, equity, and access (IDEA) in gynecologic cancer clinical trials: A joint statement from GOG foundation and Society of Gynecologic Oncology (SGO). Gynecol Oncol 2023; 174:278-287. [PMID: 37315373 DOI: 10.1016/j.ygyno.2023.05.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2023] [Revised: 05/08/2023] [Accepted: 05/10/2023] [Indexed: 06/16/2023]
Affiliation(s)
- B Pothuri
- NYU Langone Health and Laura & Isaac Perlmutter Cancer Center, New York, NY, USA.
| | - S V Blank
- Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, Blavatnik Family Women's Health Research Institute, New York, MY, USA
| | - T K Myers
- University of Massachusetts-Baystate, Springfield, MA, USA
| | - J F Hines
- University of Connecticut Health System, Farmington, CT, USA
| | - L M Randall
- Virginia Commonwealth University, Richmond, VA, USA
| | - R E O'Cearbhaill
- Memorial Sloan Kettering Cancer Center; Weill Cornell Medical College, New York, NY, USA
| | | | - R N Eskander
- University of California, San Diego Moores Cancer Center, La Jolla, CA, USA
| | - A Alvarez Secord
- Duke Cancer Institute, Duke University Health System, Durham, NC, USA
| | - R L Coleman
- Texas Oncology, US Oncology Network, The Woodlands, TX, USA
| | - J L Walker
- Stephenson Cancer Center, Oklahoma City, OK, USA
| | - B J Monk
- University of Arizona College of Medicine, Phoenix, AZ, USA
| | - K N Moore
- Stephenson Cancer Center, Oklahoma City, OK, USA
| | - D M O'Malley
- The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center Columbus, OH, USA
| | - L J Copeland
- The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center Columbus, OH, USA
| | - T J Herzog
- University of Cincinnati Cancer Center, University of Cincinnati, Cincinnati, OH, USA
| |
Collapse
|
3
|
Banerjee S, Richardson D, Concin N, Monk B, Mirza M, Coleman R, Ray-Coquard I, Pothuri B, Marth C, Demars L, Bradshaw C, Dicristo C, Mosher R, Drapkin R. 3P NaPi2b expression in high grade serous ovarian cancer: Results from combined data sets. ESMO Open 2023. [DOI: 10.1016/j.esmoop.2023.100857] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/27/2023] Open
|
4
|
Oaknin A, Pothuri B, Gilbert L, Sabatier R, Brown J, Ghamande S, Mathews C, O'Malley D, Boni V, Gravina A, Banerjee S, Miller R, Pikiel J, Mirza M, Duan T, Han X, Zildjian S, Dewal N, J.Veneris, Tinker A. 547P Efficacy of dostarlimab in endometrial cancer (EC) by molecular subtype: A post hoc analysis of the GARNET study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.675] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
5
|
Gonzalez Martin A, Pothuri B, Vergote I, Graybill W, Mirza M, Mccormick C, Lorusso D, Freyer G, Backes F, Baumann K, Redondo Sanchez A, Moore R, Vulsteke C, O'Cearbhaill R, Malinowska I, Shtessel L, Compton N, Monk B. 530P PRIMA/ENGOT-OV26/GOG-3012 study: Updated long-term PFS and safety. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.658] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
6
|
Karpel H, Pothuri B. 131P Frequency of germline testing after tumor sequencing by cancer type. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
7
|
Tinker A, Pothuri B, Gilbert L, Sabatier R, Brown J, Ghamande S, Mathews C, O'Malley D, Boni V, Gravina A, Banerjee S, Miller R, Pikiel J, Mirza M, Duan T, Antony G, Zildjian S, Zografos E, Veneris J, Oaknin A. 548P Progression-free survival (PFS) and overall survival (OS) in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability–high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC) treated with dostarlimab in the GARNET study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.676] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
8
|
O'Cearbhaill RE, Clark L, Eskander RN, Gaillard S, Moroney J, Pereira E, Pothuri B. Immunotherapy toxicities: An SGO clinical practice statement. Gynecol Oncol 2022; 166:25-35. [PMID: 35597686 PMCID: PMC10566626 DOI: 10.1016/j.ygyno.2022.05.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2022] [Revised: 05/03/2022] [Accepted: 05/04/2022] [Indexed: 11/23/2022]
Affiliation(s)
- R E O'Cearbhaill
- Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.
| | - L Clark
- University of North Carolina, Chapel Hill, NC, USA
| | - R N Eskander
- University of California, San Diego, Moores Cancer Center, La Jolla, CA, USA
| | - S Gaillard
- Johns Hopkins University, Baltimore, MD, USA
| | - J Moroney
- University of Chicago Comprehensive Cancer Center, Chicago, IL, USA
| | | | - B Pothuri
- New York University School of Medicine, New York, NY, USA
| |
Collapse
|
9
|
Oaknin A, Gilbert L, Tinker A, Brown J, Mathews C, Press J, Sabatier R, O'Malley D, Samouelian V, Boni V, Duska L, Ghamande S, Ghatage P, Kristeleit R, Leath C, Han X, Kumar S, Duan T, Im E, Pothuri B. 76P Analysis of antitumor activity of dostarlimab by tumor mutational burden (TMB) in patients (pts) with endometrial cancer (EC) in the GARNET trial. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.356] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
10
|
Domogauer J, Duckworth T, Osterman S, Pothuri B, Boyd L, Salame G, Kehoe S, Schiff P, Lymberis S. Intraoperative Ultrasound Guided Intracavitary Brachytherapy: Improving Toxicity and Precision of Tandem Applicator Placement in Cervical Cancer. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.2610] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
11
|
Margolis B, Andriani L, Baumann K, Hirsch A, Lutz K, Curtin J, Pothuri B. Opioid-free gynecologic surgery: A prospective quality improvement initiative. Gynecol Oncol 2020. [DOI: 10.1016/j.ygyno.2020.05.486] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
12
|
Heitz F, Valabrega G, Pothuri B, Oaknin A, Graybill W, Sánchez AB, McCormick C, Baurain JF, Hoskins P, Denys H, O’Cearbhaill RE, Hietanen S, Moore RG, Knudsen AØ, de La Motte Rouge T, Levy T, Li Y, Gupta D, Monk BJ, González-Martín A. Efficacy and safety of niraparib in older patients with advanced ovarian cancer (OC): results from the PRIMA/ENGOT-OV26/GOG-3012 trial. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- F Heitz
- Kliniken Essen-Mitte, Department for Gynecology and Gynecologic Oncology
| | - G Valabrega
- FPO-IRCCS Candiolo, Candiolo Cancer Institute
- University of Torino, Department of Oncology
| | - B Pothuri
- Gynecologic Oncology Group (GOG) and Perlmutter Cancer Center, NYU Langone Health, Department of Obstetrics/Gynecology
| | - A Oaknin
- Vall d´Hebron University Hospital and Vall d´Hebron Institute of Oncology (VHIO)
| | | | - AB Sánchez
- Hospital General Universitario de Elche, Unit of Genetic Counseling in Cancer, Medical Oncology Department
| | | | - JF Baurain
- Université Catholique de Louvain and Cliniques Universitaires Saint-Luc
| | - P Hoskins
- British Columbia Cancer Agency, Vancouver Centre, Medical Oncology
| | | | - RE O’Cearbhaill
- Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, Department of Medicine
| | - S Hietanen
- Turku University Hospital, Department of Obstetrics and Gynecology
| | - RG Moore
- University of Rochester, Division of Gynecologic Oncology, Wilmot Cancer Institute, Department of Obstetrics and Gynecology
| | | | | | - T Levy
- Wolfson Medical Center, Sackler School of Medicine, Tel Aviv University, Department of Obstetrics and Gynecology
| | | | | | - BJ Monk
- Arizona Oncology (US Oncology Network), University of Arizona College of Medicine
| | - A González-Martín
- Grupo Español de Investigación en Cáncer de Ovario (GEICO) and Clínica Universidad de Navarra, Medical Oncology Department
| |
Collapse
|
13
|
Baumann K, Brodsky A, Bhuptani B, Lutz K, Gerber D, Keith N, Ginsburg O, Smith J, Levine D, Pothuri B. Why do patients decline cascade testing in families with an identified mutation associated with hereditary gynecologic cancers? Gynecol Oncol 2020. [DOI: 10.1016/j.ygyno.2020.05.442] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
14
|
Fehniger J, Lee S, Pothuri B. Mutations in HRD-associated genes in ovarian cancer patients: Expanding PARP inhibitor eligibility. Gynecol Oncol 2020. [DOI: 10.1016/j.ygyno.2020.05.106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
15
|
Heitz F, Pothuri B, Han S, Chase D, Burger R, Gaba L, Van Le L, Guerra E, Bender D, Korach J, Cloven N, Follana P, Baurain JF, Pisano C, Peen U, Maenpaa J, Bacque E, Li Y, González-Martin A, Monk BJ. Patient-reported outcomes (PRO) in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718223] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- F Heitz
- Kliniken Essen-Mitte, Department for Gynecology and Gynecologic Oncology
| | - B Pothuri
- Gynecologic Oncology Group (GOG) and Perlmutter Cancer Center, NYU Langone Health, Department of Obstetrics/Gynecology
| | - S Han
- University Hospitals Leuven, Department of Obstetrics and Gynecology
| | - D Chase
- Arizona Oncology (US Oncology Network), University of Arizona College of Medicine
| | | | - L Gaba
- Hospital Clinic de Barcelona, Medical Oncology Department
| | - L Van Le
- University of North Carolina at Chapel Hill, Department of Ob/Gyn, Division of Gynecologic Oncology
| | - E Guerra
- Hospital Ramon y Cajal, Medical Oncology Department, Breast and Gynecological Cancer Unit
| | - D Bender
- University of Iowa, Department of Obstetrics and Gynecology
| | - J Korach
- The Chaim Sheba Medical Center, Sackler Medical School Tel Aviv University, Department of Oncology
| | | | - P Follana
- GINECO and Centre Antoine Lacassagne
| | - JF Baurain
- Université Catholique de Louvain and Cliniques Universitaires Saint-Luc
| | - C Pisano
- Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Department of Urology and Gynecology
| | - U Peen
- Herlev University Hospital
| | | | | | | | - A González-Martin
- Grupo Español de Investigación en Cáncer de Ovario (GEICO) and Clínica Universidad de Navarra, Medical Oncology Department
| | - BJ Monk
- Arizona Oncology (US Oncology Network), University of Arizona College of Medicine
| |
Collapse
|
16
|
Pothuri B, Han S, Chase D, Heitz F, Burger R, Gaba L, Van Le L, Guerra E, Bender D, Korach J, Cloven N, Follana P, Baurain JF, Pisano C, Peen U, Maenpaa J, Bacqué E, Li Y, Martín AG, Monk B. 810MO Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.949] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
17
|
Oaknin A, Gilbert L, Tinker A, Sabatier R, Boni V, O'Malley D, Ghamande S, Duska L, Ghatage P, Guo W, Im E, Pothuri B. LBA36 Safety and antitumor activity of dostarlimab in patients (pts) with advanced or recurrent DNA mismatch repair deficient (dMMR) or proficient (MMRp) endometrial cancer (EC): Results from GARNET. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.2266] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
18
|
Valabrega G, Pothuri B, Oaknin A, Graybill W, Sánchez A, Mccormick C, Baurain JF, Hoskins P, Denys H, O’Cearbhaill R, Heitanen S, Moore R, Knudsen A, de La Motte Rouge T, Heitz F, Levy T, Li Y, Gupta D, Monk B, Martín AG. 819P Efficacy and safety of niraparib in older patients (pts) with advanced ovarian cancer (OC): Results from the PRIMA/ENGOT-OV26/GOG-3012 trial. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.958] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
19
|
|
20
|
Sinno A, Pinkerton J, Febbraro T, Jones N, Khanna N, Temkin S, Iglesias D, Pothuri B. Hormone therapy (HT) in women with gynecologic cancers and in women at high risk for developing a gynecologic cancer: A Society of Gynecologic Oncology (SGO) clinical practice statement. Gynecol Oncol 2020; 157:303-306. [DOI: 10.1016/j.ygyno.2020.01.035] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2019] [Revised: 01/22/2020] [Accepted: 01/23/2020] [Indexed: 10/25/2022]
|
21
|
González Martín A, Pothuri B, Vergote I, Christensen R, Graybill W, Mirza M, McCormick C, Lorusso D, Hoskins P, Freyer G, Backes F, Baumann K, Redondo A, Moore R, Vulsteke C, O’Cearbhaill R, Lund B, Li Y, Gupta D, Monk B. Niraparib therapy in patients with newly diagnosed advanced ovarian cancer (PRIMA/ENGOT-OV26/GOG-3012 study). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz394.052] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
22
|
Brodsky A, Gerber D, Lutz K, Reese E, Pothuri B, Kim A. Medical marijuana for palliation of symptoms in women with gynecologic cancers. Gynecol Oncol 2019. [DOI: 10.1016/j.ygyno.2019.04.380] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
23
|
Monk B, Mirza M, Vergote I, Li Y, Malinowska I, Gupta D, Graybill W, Pothuri B, Gonzalez-Martin A. A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight and platelet count: Blinded pooled interim safety data from the ENGOT-OV26/PRIMA study. Gynecol Oncol 2019. [DOI: 10.1016/j.ygyno.2019.04.018] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
24
|
Gerber D, Curtin J, Saleh M, Boyd L, Lymberis S, Schiff P, Pothuri B, Lee J. Gastrointestinal fistula formation in cervical cancer patients who received bevacizumab. Gynecol Oncol 2019. [DOI: 10.1016/j.ygyno.2019.04.383] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
25
|
Pothuri B, Sawaged Z, Lee J, Musa F, Lutz K, Reese E, Blank S, Boyd L, Curtin J, Li X, Goldberg J, Muggia F. A phase II feasibility study of nab-paclitaxel and carboplatin in chemotherapy naïve epithelial neoplasms of the uterus. Gynecol Oncol 2019. [DOI: 10.1016/j.ygyno.2019.04.571] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
26
|
Brodsky A, Lee J, Asgari S, Fehniger J, Levine D, Pothuri B. Genetic counselor involvement with abnormal immunohistochemistry results improves genetic testing in patients with endometrial cancer. Gynecol Oncol 2019. [DOI: 10.1016/j.ygyno.2019.04.665] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
27
|
Gonzalez A, Mirza M, Vergote I, Li Y, Hazard S, Clark R, Graybill W, Pothuri B, Monk B. A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight (wt) and platelet (blplt) count: Blinded pooled interim safety data from the PRIMA Study. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy285.150] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
28
|
Lee J, Brodsky A, Madden N, Musselman K, Huang K, Jain S, Gerber D, Fehniger J, Pothuri B. The post-anesthesia care unit experience to enable successful and safe same-day discharge following robotic hysterectomies. Gynecol Oncol 2018. [DOI: 10.1016/j.ygyno.2018.04.520] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
29
|
Sandler G, Lee J, Jiang E, Gerber D, Fehniger J, Musselman K, Madden N, Boyd L, Pothuri B. Mini-laparotomy for large specimen retrieval in robotic gynecologic surgery: Key to a successful minimally invasive procedure. Gynecol Oncol 2018. [DOI: 10.1016/j.ygyno.2018.04.245] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
30
|
Gerber D, Khouri O, Smith M, Lee J, Grifo J, Pothuri B, Boyd L. An opportunity lost: Low rates of fertility counseling in pathogenic BRCA mutation carriers. Gynecol Oncol 2018. [DOI: 10.1016/j.ygyno.2018.04.494] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
31
|
Gerber D, Olsen A, Lee J, Fehniger J, Asgari S, Cantor A, Martineau J, Ginsburg O, Smith J, Levine D, Pothuri B. Risk-reducing surgery for BRCA mutations: Are we adhering to the guidelines? Gynecol Oncol 2018. [DOI: 10.1016/j.ygyno.2018.04.243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
32
|
Gonzalez Martin A, Rojas L, Braly P, Barter J, O'Malley D, Oza A, Haggerty A, Vulsteke C, Provencher D, Graybill W, Li Y, Malinowska I, Mirza M, Vergote I, Pothuri B, Monk B. A randomized, double-blind, placebo-controlled multicenter phase 3 trial of niraparib maintenance treatment in patients with advanced ovarian cancer following frontline chemotherapy. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx372.057] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
33
|
Madden N, Frey M, Lee J, Musselman K, Chern J, Joo L, Blank S, Pothuri B. Safety of robotic-assisted gynecologic surgery and early hospital discharge in elderly patients. Gynecol Oncol 2017. [DOI: 10.1016/j.ygyno.2017.03.403] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
34
|
Foley C, Lee J, Timor Tritsch I, Blank S, Pothuri B, Curtin J, Boyd L. Reoperation and recurrence rates in women undergoing conservative surgery for low malignant potential tumors. Gynecol Oncol 2017. [DOI: 10.1016/j.ygyno.2017.03.101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
35
|
Kim S, Frey M, Madden N, Musselman K, Chern J, Lee J, Boyd L, Blank S, Pothuri B, Curtin J. How old is too old: Safety of minimally invasive gynecologic surgery and early hospital discharge in the oldest elderly. Gynecol Oncol 2017. [DOI: 10.1016/j.ygyno.2017.03.327] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
36
|
Comfort A, Frey M, Musselman K, Chern J, Lee J, Joo L, Radford M, Ford S, Blank S, Boyd L, Curtin J, Pothuri B. Predictors of port site hernia necessitating operative intervention in patients undergoing robotic surgery. Gynecol Oncol 2017. [DOI: 10.1016/j.ygyno.2017.03.399] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
37
|
Musselman K, Frey M, Sapra K, Madden N, Lee J, Chern J, Blank S, Pothuri B. Indication for robotic-assisted surgery influences perioperative outcomes and hospital readmissions among women undergoing gynecologic procedures. Gynecol Oncol 2017. [DOI: 10.1016/j.ygyno.2017.03.336] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
38
|
David-West G, Musa F, Frey M, Boyd L, Pothuri B, Curtin J, Blank S. Cross-sectional study on the impact of a natural disaster on delivery of gynecologic oncology care. Gynecol Oncol 2014. [DOI: 10.1016/j.ygyno.2014.03.394] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
39
|
Musa F, Alard A, Blank S, Pothuri B, Curtin J, Schneider R. mTOR complex inhibition as a novel therapeutic strategy in high-grade papillary serous ovarian cancer. Gynecol Oncol 2014. [DOI: 10.1016/j.ygyno.2014.03.314] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
40
|
Abstract
Ovarian cancer is the deadliest among gynecologic cancers. Hereditary cancer related to BRCA1/2 gene mutations account for ~10%-12% of ovarian cancers. The BRCA1/2 proteins are important in homologous recombination (HR) repair of DNA. Patients with BRCA1/2 mutations have been reported to have improved chemosensitivity to platinum agents, longer disease-free intervals, and longer survivals than nonhereditary counterparts. Recent interest in poly(ADP-ribosyl) polymerase (PARP) proteins which are key components of base excision repair, has led to the development of PARP inhibitors; tumors arising in BRCA1/2 mutation carriers and/or with HR deficiency (HRD) are particularly sensitive to the action of these drugs. As 60%-80% of all advanced ovarian cancers are high-grade serous type, exhibiting HRD in at least 50% (referred as BRCAness) future antitumor strategies may depend on identifying these defects through molecular testing. Once HRD becomes amenable to routine testing, a larger group of ovarian cancer patients than are currently considered for PARP inhibitor trials, may benefit from such targeted therapy.
Collapse
Affiliation(s)
- B Pothuri
- Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, NYU School of Medicine, New York, USA
| |
Collapse
|
41
|
Ling H, Muggia F, Speyer J, Curtin J, Blank S, Boyd L, Pothuri B, Li X, Goldberg J, Tiersten A. Combination of irinotecan and bevacizumab for heavily pretreated recur- rent ovarian cancer: A phase II trial. Gynecol Oncol 2013. [DOI: 10.1016/j.ygyno.2013.04.085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
42
|
Blank S, Greenwald J, Boyd L, Pothuri B, Curtin J. Trial design and endpoint definition for conservative management of endometrial neoplasia. Gynecol Oncol 2013. [DOI: 10.1016/j.ygyno.2013.04.218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
43
|
Verschraegen CF, Czok S, Muller CY, Boyd L, Lee SJ, Rutledge T, Blank S, Pothuri B, Eberhardt S, Muggia F. Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer. Ann Oncol 2012; 23:3104-3110. [PMID: 22851407 DOI: 10.1093/annonc/mds172] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
BACKGROUND Suppression of neoangiogenesis and pegylated liposomal doxorubicin (PLD) each contribute to the management of platinum-resistant/refractory ovarian cancer. The aim of this study is to test the combination of bevacizumab and PLD in women with resistant or refractory ovarian cancer. METHODS Eligibility criteria were no more than two prior treatments with platinum-containing regimens and one additional regimen, without anthracyclines. Treatment was administered every 3 weeks (bevacizumab 15 mg/kg beginning on cycle 2 and PLD 30 mg/m(2)). The primary end point was progression-free survival (PFS) at 6 months; the secondary end points included side-effects, overall response rates (ORR) and survival (OS). RESULTS Forty-six patients were enrolled. The average number of courses administered was 7. The median PFS was 6.6 months (range 1-24.6 months) according to Gynecologic Cancer Intergroup Committee (GCIC) criteria and 7.8 months (range 2-13.3 months) according to Response Evaluation Criteria in Solid Tumors (RECIST). The median OS was 33.2 months (range 3-37.5+ months). The ORR was 30.2% [95% confidence interval (CI) 17.2-46.1] and the clinical benefit rate (CBR) was 86.1% (95% CI 72.1-94.7). Adverse events included mucosal and dermal erosions (30% grade 3) and asymptomatic cardiac dysfunction. Additional toxic effects included hypertension, headache, renal dysfunction and proteinuria, wound healing delay, and one episode each of central nervous system (CNS) ischemia and hemolytic uremic syndrome. CONCLUSION PLD with bevacizumab has improved activity in recurrent ovarian cancer with increased toxicity.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors/adverse effects
- Angiogenesis Inhibitors/therapeutic use
- Antibiotics, Antineoplastic/adverse effects
- Antibiotics, Antineoplastic/therapeutic use
- Antibodies, Monoclonal, Humanized/adverse effects
- Antibodies, Monoclonal, Humanized/therapeutic use
- Antineoplastic Combined Chemotherapy Protocols/adverse effects
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Bevacizumab
- Bridged-Ring Compounds/pharmacology
- Carcinoma, Ovarian Epithelial
- Disease-Free Survival
- Doxorubicin/adverse effects
- Doxorubicin/therapeutic use
- Drug Resistance, Neoplasm
- Female
- Humans
- Middle Aged
- Neoplasm Recurrence, Local/drug therapy
- Neoplasms, Glandular and Epithelial/drug therapy
- Neoplasms, Glandular and Epithelial/mortality
- Ovarian Neoplasms/drug therapy
- Ovarian Neoplasms/mortality
- Platinum/pharmacology
- Taxoids/pharmacology
- Treatment Outcome
Collapse
Affiliation(s)
- C F Verschraegen
- Department of Hematology/Oncology, University of Vermont Cancer Center, Burlington.
| | - S Czok
- Departments of Obstetrics and Gynecology, New York University Cancer Institute, New York
| | - C Y Muller
- Departments of Gynecologic Oncology, USA
| | - L Boyd
- Departments of Obstetrics and Gynecology, New York University Cancer Institute, New York
| | - S J Lee
- Departments of Mathematics, USA
| | - T Rutledge
- Departments of Gynecologic Oncology, USA
| | - S Blank
- Departments of Obstetrics and Gynecology, New York University Cancer Institute, New York
| | - B Pothuri
- Departments of Obstetrics and Gynecology, New York University Cancer Institute, New York
| | - S Eberhardt
- Radiology, University of New Mexico Cancer Center, Albuquerque, USA
| | - F Muggia
- Departments of Medicine, New York University Cancer Institute, New York
| |
Collapse
|
44
|
Pothuri B, Sparano J, Blank S, Curtin J, Chuang E, Hershman D, Tiersten A, Liebes L, Chen A, Muggia F. Phase I study of the PARP inhibitor ABT-888 (veliparib) and pegylated liposomal doxorubicin (PLD) in recurrent ovarian (ov) and breast (br) cancers. Gynecol Oncol 2012. [DOI: 10.1016/j.ygyno.2011.12.053] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
45
|
Zechmeister J, Pua T, Novetsky A, Ferrante K, Pothuri B. A Prospective Comparison of Post-Operative Pain in Robotic Versus Laparoscopic Gynecologic Surgery. J Minim Invasive Gynecol 2011. [DOI: 10.1016/j.jmig.2011.08.371] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
46
|
Pua T, Jewell A, Novetsky A, Lee J, Friedman K, Whyte J, Boyd L, Pothuri B, Curtin J, Blank S. Incidental gynecologic FDG-PET/CT findings in women with a history of breast cancer. Gynecol Oncol 2011. [DOI: 10.1016/j.ygyno.2010.12.149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
47
|
Boyd LR, Novetsky A, Pua TL, Pothuri B, Curtin JP, Wallach RC, Blank SV. Intraperitoneal chemotherapy: Who, what, when, and how in diverse academic settings. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.5114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
48
|
Muggia FM, Boyd L, Liebes L, Downey A, Muller C, Pothuri B, Blank S, Rutledge T, Fishman D, Verschraegen C. Pegylated liposomal doxorubicin (PLD) with bevacizumab (B) in second-line treatment of ovarian cancer (OC): Pharmacokinetics (PK), safety, and preliminary outcome results. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.5548] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5548 Background: PLD activity in platinum-resistant OC is modest. B, with its activity in platinum(Plat)-sensitive and Plat-resistant patients (pts), has not been combined with PLD. PLD intratumoral concentrations, if affected by B, might be reflected in PLD PK. This phase II study of PLD + B was started in 2007 to accrue 48 pts, unless 4 serious (> grade 3) adverse events (AEs) supervened. Methods: Improvement in progression-free survival (PFS) at 6 m from 25 to 40% at 6 m in Plat-resistant OC is primary endpoint. PK of PLD alone at 1h, d 7 and d 21 (cycle 1) vs with B (cycle 2), safety, and response rates (RECIST and CA125 criteria) were secondary endpoints. Dosing: PLD 30 mg/m2 followed by B 15 mg/kg on cycles 2–7 (with option to continue) d 1 every 3 w. Pts recurring within 6 m of platinum-based treatment for OC after < 3 prior regimens (but no PLD or B) were eligible. Exclusions: bowel obstruction, prior perforation, uncontrolled hypertension, or vascular disease. Hematologic, mucocutaneous and renal toxicities were evaluated prior to each cycle, MUGA scans every third cycle; disease status by CA125 and/or RECIST every third cycle. Results: 21 of 24 pts enrolled to date are evaluable. Median age is 65, range 52–83; most had 2 prior chemotherapy regimens. Median 6 (range 3–12) cycles were given with 6 off study with progression at 3–7 cycles. RECIST and CA125 responses are under review; in 11 pts with baseline CA125 of > 40 IU/mL, median increase was 31% by cycle 2; later falling to -57%. AEs did not exceed grade 3; hand-foot syndrome led to PLD dose reduction in 8 pts (33%); asymptomatic decreases in left ventricular ejection fraction (LVEF) >10% in 3 pts were noted, with treatment discontinuation in 1. The mean (±SEM) secondary PK parameter estimates for Cmax, AUC, and elimination half life were 4.5 ± 0.5 ug/mL, 651.7 ± 61 ug/mL x h, and 93.3 ± 19.7 h, respectively. Conclusions: Cycles 1 and 2 PLD PK do not differ. PLD + B is tolerable with PLD dose modifications. Declines in LVEF in 1 institution have uncertain causality. Midway into the trial, safety and time on study encourage completion for study primary endpoint. [Table: see text]
Collapse
Affiliation(s)
- F. M. Muggia
- NYU School of Medicine, New York, NY; University of New Mexico, Albuquerque, NM; University of New Mexico, Albuquerque, NH
| | - L. Boyd
- NYU School of Medicine, New York, NY; University of New Mexico, Albuquerque, NM; University of New Mexico, Albuquerque, NH
| | - L. Liebes
- NYU School of Medicine, New York, NY; University of New Mexico, Albuquerque, NM; University of New Mexico, Albuquerque, NH
| | - A. Downey
- NYU School of Medicine, New York, NY; University of New Mexico, Albuquerque, NM; University of New Mexico, Albuquerque, NH
| | - C. Muller
- NYU School of Medicine, New York, NY; University of New Mexico, Albuquerque, NM; University of New Mexico, Albuquerque, NH
| | - B. Pothuri
- NYU School of Medicine, New York, NY; University of New Mexico, Albuquerque, NM; University of New Mexico, Albuquerque, NH
| | - S. Blank
- NYU School of Medicine, New York, NY; University of New Mexico, Albuquerque, NM; University of New Mexico, Albuquerque, NH
| | - T. Rutledge
- NYU School of Medicine, New York, NY; University of New Mexico, Albuquerque, NM; University of New Mexico, Albuquerque, NH
| | - D. Fishman
- NYU School of Medicine, New York, NY; University of New Mexico, Albuquerque, NM; University of New Mexico, Albuquerque, NH
| | - C. Verschraegen
- NYU School of Medicine, New York, NY; University of New Mexico, Albuquerque, NM; University of New Mexico, Albuquerque, NH
| |
Collapse
|
49
|
Gogoi R, Brusati A, Liu M, Curtin JP, Blank SV, Pothuri B. Thromboembolism and outcomes in patients with gynecologic malignancies. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.20548] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
50
|
Long K, Malik R, Curtin JP, Pothuri B. IP catheter complications and associated risk factors in patients with ovarian cancer. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.5525] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|